{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:31:54Z","timestamp":1781847114102,"version":"3.54.5"},"reference-count":38,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.3892\/ol.2017.6355","type":"journal-article","created":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T07:20:41Z","timestamp":1496906441000},"page":"1648-1656","source":"Crossref","is-referenced-by-count":22,"title":["Cytotoxic effects of zoledronic acid-loaded hydroxyapatite and bone cement in malignant tumors"],"prefix":"10.3892","volume":"14","author":[{"given":"Kazutaka","family":"Koto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Sawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eishi","family":"Ashihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyuki","family":"Horii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikazu","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2017,6,8]]},"reference":[{"key":"key20180108114926_b1-ol-0-0-6355","first-page":"305","volume-title":"Dahlin's bone tumors, General Aspects and Data on 10,165 Cases","author":"Unni","year":"2010"},{"key":"key20180108114926_b2-ol-0-0-6355","first-page":"49","article-title":"Clinicopathological evaluation of metastatic carcinomas of bone: A retrospective analysis of 114 cases over 10 years","volume":"38","author":"Desai","year":"1995","journal-title":"Indian J Pathol Microbiol"},{"key":"key20180108114926_b3-ol-0-0-6355","first-page":"81","article-title":"Metastatic lesions of the proximal femur","volume":"69","author":"Doung","year":"2011","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"key20180108114926_b4-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3109\/17453674.2011.645197","article-title":"Surgery of skeletal metastases in 306 patients with prostate cancer","volume":"83","author":"Weiss","year":"2012","journal-title":"Acta Orthop"},{"key":"key20180108114926_b5-ol-0-0-6355","first-page":"1","article-title":"Failures after operation for skeletal metastatic lesions of long bones","author":"Wedin","year":"1999","journal-title":"Clin Orthop Relat Res"},{"key":"key20180108114926_b6-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"2pp1","DOI":"10.1080\/000164701753759546","article-title":"Surgical treatment for pathologic fracture","volume":"72","author":"Wedin","year":"2001","journal-title":"Acta Orthop Scand Suppl"},{"key":"key20180108114926_b7-ol-0-0-6355","first-page":"556","article-title":"Surgical treatment of pathologic fracture of the femur","volume":"13","author":"Chien","year":"1997","journal-title":"Kaohsiung J Med Sci"},{"key":"key20180108114926_b8-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S8756-3282(99)00116-7","article-title":"Bisphosphonates: From the laboratory to the clinic and back again","volume":"25","author":"Russell","year":"1999","journal-title":"Bone"},{"key":"key20180108114926_b9-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"S840","DOI":"10.1002\/cncr.11128","article-title":"Antitumor effects of bisphosphonates","volume":"97","author":"Green","year":"2003","journal-title":"Cancer"},{"key":"key20180108114926_b10-ol-0-0-6355","first-page":"2602","article-title":"Bisphosphonate treatment inhibits the growth of prostate cancer cells","volume":"61","author":"Lee","year":"2001","journal-title":"Cancer Res"},{"key":"key20180108114926_b11-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/jor.20177","article-title":"Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells","volume":"24","author":"Kubo","year":"2006","journal-title":"J Orthop Res"},{"key":"key20180108114926_b12-ol-0-0-6355","first-page":"233","article-title":"Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents","volume":"24","author":"Koto","year":"2010","journal-title":"Oncol Rep"},{"key":"key20180108114926_b13-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.canlet.2005.06.041","article-title":"The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosis","volume":"238","author":"Horie","year":"2006","journal-title":"Cancer Lett"},{"key":"key20180108114926_b14-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/sj.bjc.6603548","article-title":"Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma","volume":"96","author":"Horie","year":"2007","journal-title":"Br J Cancer"},{"key":"key20180108114926_b15-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2008.09.026","article-title":"Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model","volume":"274","author":"Koto","year":"2009","journal-title":"Cancer Lett"},{"key":"key20180108114926_b16-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","article-title":"The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel","volume":"84","author":"Jagdev","year":"2001","journal-title":"Br J Cancer"},{"key":"key20180108114926_b17-ol-0-0-6355","first-page":"144","volume-title":"Basic Histology, Text & Atlas","author":"Junqueira","year":"2003","edition":"10th"},{"key":"key20180108114926_b18-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1302\/0301-620X.82B8.11194","article-title":"Use of hydroxyapatite to fill cavities after excision of benign bone tumours","volume":"82","author":"Yamamoto","year":"2000","journal-title":"J Bone Joint Surg Br"},{"key":"key20180108114926_b19-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1302\/0301-620X.72B2.2155908","article-title":"The use of calcium hydroxyapatite ceramic in bone tumour surgery","volume":"72","author":"Uchida","year":"1990","journal-title":"J Bone Joint Surg Br"},{"key":"key20180108114926_b20-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1302\/0301-620X.74B4.1320622","article-title":"Calcium hydroxyapatite ceramic used as a delivery system for antibiotics","volume":"74","author":"Shinto","year":"1992","journal-title":"J Bone Joint Surg Br"},{"key":"key20180108114926_b21-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00264-006-0156-1","article-title":"Use of purified beta-tricalcium phosphate for filling defects after curettage of benign bone tumours","volume":"30","author":"Hirata","year":"2006","journal-title":"Int Orthop"},{"key":"key20180108114926_b22-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0304-3835(96)04337-6","article-title":"Sustained release of adriamycin from implanted hydroxyapatite blocks for the treatment of experimental osteogenic sarcoma in mice","volume":"107","author":"Itokazu","year":"1996","journal-title":"Cancer Lett"},{"key":"key20180108114926_b23-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/(SICI)1097-0215(19980504)76:3<418::AID-IJC21>3.0.CO;2-5","article-title":"Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung","volume":"76","author":"Asai","year":"1998","journal-title":"Int J Cancer"},{"key":"key20180108114926_b24-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/jnci\/59.1.221","article-title":"One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice","volume":"59","author":"Fogh","year":"1977","journal-title":"J Natl Cancer Inst"},{"key":"key20180108114926_b25-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z","article-title":"Characterization of a newly derived human sarcoma cell line (HT-1080)","volume":"33","author":"Rasheed","year":"1974","journal-title":"Cancer"},{"key":"key20180108114926_b26-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.canlet.2003.09.031","article-title":"Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1","volume":"204","author":"Kawai","year":"2004","journal-title":"Cancer Lett"},{"key":"key20180108114926_b27-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/BF02617972","article-title":"In vitro cultivation of human renal cell cancer. II. Characterization of cell lines","volume":"14","author":"Williams","year":"1978","journal-title":"In Vitro"},{"key":"key20180108114926_b28-ol-0-0-6355","first-page":"524","article-title":"Chromosomal analysis of human prostatic adenocarcinoma cell lines","volume":"40","author":"Ohnuki","year":"1980","journal-title":"Cancer Res"},{"key":"key20180108114926_b29-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/jnci\/51.5.1417","article-title":"In vitro cultivation of human tumors: Establishment of cell lines derived from a series of solid tumors","volume":"51","author":"Giard","year":"1973","journal-title":"J Natl Cancer Inst"},{"key":"key20180108114926_b30-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0022-1759(89)90397-9","article-title":"Re-examination and further development of a precise and rapid dye method for measuring cell growth\/cell kill","volume":"119","author":"Hansen","year":"1989","journal-title":"J Immunol Methods"},{"key":"key20180108114926_b31-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jso.2930310402","article-title":"Tumor measurement in the nude mouse","volume":"31","author":"Euhus","year":"1986","journal-title":"J Surg Oncol"},{"key":"key20180108114926_b32-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/BF00300234","article-title":"Determination of subcutaneous tumor size in athymic (nude) mice","volume":"24","author":"Tomayko","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20180108114926_b33-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2342-8-16","article-title":"Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper","volume":"8","author":"Jensen","year":"2008","journal-title":"BMC Med Imaging"},{"key":"key20180108114926_b34-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2106\/JBJS.H.01679","article-title":"Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines","volume":"92","author":"Zwolak","year":"2010","journal-title":"J Bone Joint Surg Am"},{"key":"key20180108114926_b35-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1039\/B512310K","article-title":"\u2018Magic bullets\u2019 for bone diseases: Progress in rational design of bone-seeking medicinal agents","volume":"36","author":"Zhang","year":"2007","journal-title":"Chem Soc Rev"},{"key":"key20180108114926_b36-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s10147-016-1019-4","article-title":"Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab","volume":"21","author":"Yamasaki","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"key20180108114926_b37-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00280-007-0580-y","article-title":"Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells","volume":"62","author":"Kubo","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20180108114926_b38-ol-0-0-6355","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/jnci\/djn240","article-title":"Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer","volume":"100","author":"Ottewell","year":"2008","journal-title":"J Natl Cancer Inst"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T15:22:46Z","timestamp":1569424966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2017.6355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,8]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,6,8]]},"published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.3892\/ol.2017.6355"],"URL":"https:\/\/doi.org\/10.3892\/ol.2017.6355","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,8]]}}}